Andere Sprachen ClearPoint Neuro, Inc.

Aktien

A2PZ3E

US18507C1036

CLPT

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:07:30 02.05.2024			% 5 Tage	% 1. Jan.
5.45 ^USD	+0.55%		+2.45%	-19.88%

30.04.	Clinical Laserthermia erhält US FDA-Zulassung für das Prism Bone Anchor Accessory von ClearPoint	MT
29.04.	ClearPoint erhält FDA-Zulassung für neurochirurgische Ausrüstung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)	15:01
Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory	30.04.
CLS partner ClearPoint Neuro receives FDA 510(k) clearance for Prism Bone Anchor Accessory enabling operating room placement of laser applicators	30.04.
ClearPoint Gets FDA Clearance For Neurosurgical Equipment	29.04.
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory	29.04.
ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory	29.04.
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR Stereotactic System	25.04.
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System	24.04.
ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR? Stereotactic System	24.04.
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024	23.04.
ClearPoint Neuro feliciteert partner AviadoBio met de behandeling van de eerste patiënt in klinisch onderzoek ASPIRE-FTD, waarin AVB-101 wordt geëvalueerd voor frontotemporale dementie met GRN-mutaties	17.04.
ClearPoint Neuro si congratula con il proprio partner AviadoBio per il primo paziente trattato nello studio clinico ASPIRE-FTD, che valuta la terapia genica sperimentale AVB-101 per la demenza frontotemporale con mutazioni GRN	17.04.
ClearPoint Neuro félicite son partenaire AviadoBio pour son premier patient traité dans le cadre de son essai clinique ASPIRE-FTD évaluant l’AVB-101 dans la démence fronto-temporale avec mutations du gène GRN	17.04.
ClearPoint Neuro felicita a su socio AviadoBio por el primer paciente tratado en su ensayo clínico ASPIRE-FTD que evalúa AVB-101 en personas con demencia frontotemporal con mutaciones en el gen GRN	17.04.
ClearPoint Neuro Says Partner AviadoBio Treats First Person in Trial of AVB-101 for Frontotemporal Dementia	16.04.
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations	16.04.
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)	08.04.
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency	20.03.
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency	19.03.
ClearPoint Neuro, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ClearPoint Neuro, Inc.

Aktien

A2PZ3E

US18507C1036

CLPT

Andere Sprachen

Filter